Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Diabetic Medications to Fight Parkinson's Disease and Lewy Body Dementia
NCT06263673Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- May 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sitagliptin, dapagliflozin in Parkinson's disease (PD), Lewy body dementia (LBD), sponsored by Mayo Clinic. Started May 2024; status: completed.
02
Drugs
sitagliptindapagliflozin
03
Conditions
Parkinson's disease (PD)Lewy body dementia (LBD)
Beyond the preview
Go deeper on NCT06263673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263673.